Monteverde & Associates Launches Investigation into Bio-Techne Sale
Shareholders of Bio-Techne Corporation are facing scrutiny over the company’s proposed acquisition by Merck KGaA, with the New York-based law firm Monteverde & Associates PC questioning the fairness of the $73.00 per share cash offer currently on the table for investors.
The investigation centers on whether the deal accurately reflects the intrinsic value of the NASDAQ-listed firm. Juan Monteverde, a class action attorney at the helm of the firm based in the Empire State Building, is inviting stockholders to examine the terms of the transaction to determine if the compensation provided by Merck KGaA is sufficient. The firm, which highlights its history of recovering millions for shareholders, encourages investors to scrutinize the sale process for potential breaches of fiduciary duty.
For those holding common stock in Bio-Techne, the firm offers a consultation to discuss the implications of the buyout. Interested parties may contact the legal team via email at jmonteverde@monteverdelaw.com or by calling 212-971-1341. While the firm promotes its track record in trial and appellate courts, it notes that prior legal victories do not guarantee specific outcomes for this ongoing inquiry.
Comments (0)
No comments yet. Be the first!